The COVID-19 pandemic posed a challenge for clinical management of a new lung disease that was characterized by inflammation,endothelial cell dysfunction,and thrombosis,which occur after the replication phase of infec...The COVID-19 pandemic posed a challenge for clinical management of a new lung disease that was characterized by inflammation,endothelial cell dysfunction,and thrombosis,which occur after the replication phase of infection of severe acute respiratory syndrome coronavirus 2(SARS-CoV-2).There are many laboratory models of active SARS-CoV-2 infection in mice,reflecting an acute lung injury in an otherwise healthy animal,but there is a lack of accurate animal models of the postviral inflammatory phase of the COVID-19 lung reflecting severe disease.The monocrotaline(MCT)-treated rat is a widely used laboratory model of pulmonary hypertension(PH).Not often discussed,however,are the observed changes in inflammation,edema,fibrosis,and microthrombosis in the lung prior to PH.At the cellular level,there is loss of pneumocytes and endotheliopathy,and at the molecular level the MCT rat lung is characterized by a proinflammatory cytokine profile,namely elevated interleukin 6,transforming growth factorβand tumor necrosis factor,M1 macrophage phenotype,and dysregulation of the angiotensin converting enzyme(ACE)/ACE2 balance.The systems-level pathophysiology of the MCT-treated rat includes progressive cardiopulmonary dysfunction.The MCT-treated rat clearly differs from the COVID-19 lung in terms of the triggers for pathology,but there are many parallels apparent in both the MCT-treated rat and the COVID-19 lung.The MCT-treated rat lung as a model of the COVID-19 lung may provide an in-depth understanding of the factors that drive the lung to more severe pathology,treatments that benefit lung recovery,or the factors that prove a useful research platform for future emerging respiratory threats of similar pathology.展开更多
Pulmonary arterial hypertension （PAH） is a progressive disease associated with increased constriction and remodeling of the pulmonary vasculature. Quercetin is a natural fiavonoid and has a variety of pharmacologica...Pulmonary arterial hypertension （PAH） is a progressive disease associated with increased constriction and remodeling of the pulmonary vasculature. Quercetin is a natural fiavonoid and has a variety of pharmacological effects including improvement of endothelial cell function. However, its pharmacological effects on pulmonary hypertension have been rarely reported. We sought to observe the protective effect of quercetin in rats with monocrotaline induced PAH. We divided 30 male Sprague-Dawley rats randomly into three groups with ten rats in each group： the monocrotaline group, the quercetin group and the control group. We found that, compared with the controls, the mean pulmonary artery pressure （mPAP） and the right ventricular hypertrophy index in the monocrotaline group were significantly higher （P 〈 0.01）. Quercetin caused a significant reduction both in the mPAP and fight ventricular hypertrophy index compared with the monocrotaline group （P 〈 0.01） while no difference was found between the quercefin group and the control group （P 〉 0.05）. Monocrotaline induced a marked increase in the wall thickness （WT） in small and mid-sized pulmonary arteries compared with the controls （P 〈 0.01）. Monocrotaline also induced a marked increase in the wall area （WA） in small [（56.38 ±6.65）% in monocrotaline vs. （19.80±4.63）% in control] and mid-sized [（43.71± 5.38）% in monocrotaline vs. （14.24± 3.66）% in control] pulmonary arteries （P 〈 0.01）. Quercefin treatment markedly reduced monocrotaline induced increase in both WT and WA （P 〈 0.01）, which, however, still remained significantly elevated compared with those of the controls （P 〈 0.01）. Furthermore, compared with controls, proliferating cell nuclear antigen （PCNA） expression in the pulmonary artery tissues was markedly increased by monocrotaline [（45.59± 1.27） in monocrotaline vs. （9.64± 0.69） in controls], which was significantly attenuated by quercetin. Our animal experiment indicated that quercetin could have protective effects on monocrotaline-induced PAH.展开更多
BACKGROUND:Hepatic veno-occlusive disease(HVOD)is a severe complication of chemotherapy before hematopoietic stem cell transplantation and dietary ingestion of pyrrolizidine alkaloids.Many experimental models were est...BACKGROUND:Hepatic veno-occlusive disease(HVOD)is a severe complication of chemotherapy before hematopoietic stem cell transplantation and dietary ingestion of pyrrolizidine alkaloids.Many experimental models were established to study its mechanisms or therapy,but few are ideal.This work aimed at evaluating a rat model of HVOD induced by monocrotaline to help advance research into this disease. METHODS:Thirty-two male rats were randomly classified into 5 groups,and PBS or monocrotaline was administered (100 mg/kg or 160 mg/kg).They were sacrificed on day 7(groups A,B and D)or day 10(groups C and E).Blood samples were collected to determine liver enzyme concentrations.The weight of the liver and body and the amount of ascites were measured.Histopathological changes of liver tissue on light microscopy were assessed by a modified Deleve scoring system.The positivity of proliferating cell nuclear antigen(PCNA)was estimated. RESULTS:The rats that were treated with 160 mg/kg monocrotaline presented with severe clinical symptoms (including two deaths)and the histopathological picture of HVOD.On the other hand,the rats that were fed with 100 mg/kg monocrotaline had milder and reversible manifestations.Comparison of the rats sacrificed on day 10 with those sacrificed on day 7 showed that the positivity of PCNA increased,especially that of hepatocytes.CONCLUSIONS:Monocrotaline induces acute,dose- dependent HVOD in rats.The model is potentially reversible with a low dose,but reliable and irreversible with a higher dose.The modified scoring system seems to be more accurate than the traditional one in reflecting the histopathology of HVOD.The enhancement of PCNA positivity may be associated with hepatic tissue undergoing recovery.展开更多
Current study systematically investigated the interaction of two alkaloids, anisodine and monocrotaline, with organic cation transporter OCT1, 2, 3, MATE1 and MATE2-K by using in vitro stably transfected HEK293 cells....Current study systematically investigated the interaction of two alkaloids, anisodine and monocrotaline, with organic cation transporter OCT1, 2, 3, MATE1 and MATE2-K by using in vitro stably transfected HEK293 cells. Both anisodine and monocrotaline inhibited the OCTs and MATE transporters. The lowest IC50 was 12.9 μmol·L-1 of anisodine on OCT1 and the highest was 1.8 mmol·L-1 of monocrotaline on OCT2. Anisodine was a substrate of OCT2(Km = 13.3 ± 2.6 μmol·L-1 and Vmax = 286.8 ± 53.6 pmol/mg protein/min). Monocrotaline was determined to be a substrate of both OCT1(Km = 109.1 ± 17.8 μmol·L^-1, Vmax = 576.5 ± 87.5 pmol/mg protein/min) and OCT2(Km = 64.7 ± 14.8 μmol·L^-1, Vmax = 180.7 ± 22.0 pmol/mg protein/min), other than OCT3 and MATE transporters. The results indicated that OCT2 may be important for renal elimination of anisodine and OCT1 was responsible for monocrotaline uptake into liver. However neither MATE1 nor MATE2-K could facilitate transcellular transport of anisodine and monocrotaline. Accumulation of these drugs in the organs with high OCT1 expression(liver) and OCT2 expression(kidney) may be expected.展开更多
To observe changes in activity of superoxide dismutase (SOD) and content of malondialdehyde (MDA) in rats with monocrotaline-induced pulmonary hypertension. Methods: Adult ma1e Sprague-Dawley rats were given a single ...To observe changes in activity of superoxide dismutase (SOD) and content of malondialdehyde (MDA) in rats with monocrotaline-induced pulmonary hypertension. Methods: Adult ma1e Sprague-Dawley rats were given a single subcutaneous injection of monocrotaline (MCT, 60 mg/kg) for modeling PH. Activities of SOD and contents of MDA in plasma and pulmonary homogenate were measured by colorimetric analysis. The thickness of the media of pulmonary arterioles (external diameter <100μm) was measured using colour image analysis system. Results: Four weeks after injection of MCT, activities of SOD in venous plasma and pulmonary homogenate for MCT group were 106±45 NU/ml (P<0.05) and 317±59 NU/ml (P<0.01) respectively, whileactivities of SOD for control group were 159±28 NU/ml (P<0.05) and 505±47 NU/ml (P<0.01) respectively.COntents of MDA in venous plasma and pulmonary homogenate for MCT group were 15±5 and 59±14 μmol/L,while contents of MDA for control group were 5. 3±2. 8 and 32±19 ±mol/L. The thickness of the media of pulmonary arterioles increased significantly. Conclusion: The primary cause of PH is the injury of pulmonary vascular endothelial cells by MCT, which decreases the O2 removing ability of the lungs but increases lipid peroxidation,thus inducing PH.展开更多
Precision-cut liver slice has been successfully used to study the mechanism of drug-induced hepatotoxicity, the prediction of liver toxicity, the discovery of early hepatic toxicity biomarker and the metabolism of dru...Precision-cut liver slice has been successfully used to study the mechanism of drug-induced hepatotoxicity, the prediction of liver toxicity, the discovery of early hepatic toxicity biomarker and the metabolism of drug in liver. We detected the expression of CYP3A4, CYP2B1 + CYP2B2 and CYP2E1 in precision-cut liver slice after co-cultured with monocrotaline or Tussilago farfara alkaloids to investigate the hepatotoxicity mechanism of those drugs. After co-culturing with monocrotaline or Tussilago farfara alkaloids for 6 hours, the expression of CYP3A4 in the microsome of precision-cut liver slices was detected by Western blot, and the expressions of CYP2B1 + CYP2B2 and CYP2E1 were detected by immunofluorescence. The results showed that monocrotaline induced the expression of CYP3A4 and CYP2B1 + CYP2B2, and Tussilago farfara alkaloids obviously up-regulated the expression of CYP2E1 and CYP3A4. Thus, we conclude that the up-regulation of CYP3A4, CYP2B1 + CYP2B2 and CYP2E1 may be one of the toxic mechanisms of liver injury of those drugs.展开更多
Exercise training in pulmonary arterial hypertension(PAH)has been gaining popularity with guidelines now recommending it as an important adjunct to medical therapy.Despite improvements in function and quality of life,...Exercise training in pulmonary arterial hypertension(PAH)has been gaining popularity with guidelines now recommending it as an important adjunct to medical therapy.Despite improvements in function and quality of life,an understanding of metabolic changes and their mechanisms remain unexplored.The objective of this study was therefore to understand the metabolic basis of exercise in a monocrotaline model of PAH.24 male Wistar rats(age:8–12 weeks and mean body weight:[262.16±24.49]gms)were assigned to one of the four groups(i.e.,Control,PAH,Exercise and PAH t Exercise).The exercise groups participated in treadmill running at 13.3 m/min,five days a week for five weeks.Demographic and clinical characteristics were monitored regularly.Following the intervention,LC-MS based metabolomics were performed on blood samples from all groups at the end of five weeks.Metabolite profiling,peak identification,alignment and isotope annotation were also performed.Statistical inference was carried out using dimensionality reducing techniques and analysis of variance.Partial-least-squares discrimination analysis and variable importance in the projection scores showed that the model was reliable,and not over lifting.The analysis demonstrated significant perturbations to lipid and amino acid metabolism,arginine and homocysteine pathways,sphingolipid(p<0.05),glycerophospholipid(p<0.05)and nucleotide metabolism in PAH.Exercise,however,was seen to restore arginine(p<0.05)and homocysteine(p<0.0001)levels which were independent effects,irrespective of PAH.Dysregulated arginine and homocysteine pathways are seen in PAH.Exercise restores these dysregulated pathways and could potentially impact severity and outcome in PAH.展开更多
Objective To investigate the curative effect and possiblemechanism ofrifaximin treatment on monocrotaline-induced hepatic sinusoidal obstruction syndrome(HSOS)in mice.Methods Twenty-four male C57BL/6J mice were divide...Objective To investigate the curative effect and possiblemechanism ofrifaximin treatment on monocrotaline-induced hepatic sinusoidal obstruction syndrome(HSOS)in mice.Methods Twenty-four male C57BL/6J mice were divided into three groups and treatedwith solvent tcontrol,monocrotaline,and rifaximin,respectively.The histopathological changes of the liver and intestine were observed by hematoxylineosin staining.The differences were compared in liver parameters,serum liver enzymes,inflammatory factors,apoptotic factors,gut microbiota,and gut tight junction proteins among three groups of mice.The inter-group comparison was conducted using a t-test and one-way analysis of variance.Results The rifaximin-treated group had significantly improved liver histopathology.The serological levels of alanine aminotransferase and aspartate aminotransferase were(559.04±89.42)U/L and(676.90±106.25)U/L,respectively,which were significantly lower than those in the PA-HSOS model group[(846.05±148.46)U/L and(953.87±58.10)U/L,P<0.05],and were accompanied by lower levels of apoptotic cells and inflammatory factors.Additionally,the rifaximintreated mice group gut microbiota had higher diversity compared with the PA-HSOS group(P<0.05),and the Shannon index was 7.77±0.10 and 7.16±0.07,respectively,indicating apparent differences in microbiota among different groups.The abundance of Firmicutes in the rifaximin group was 39.58%±0.56%,which was significantly higher than that in the model group(24.25%±0.64%,P<0.05),while the abundance of Bacteroidetes was 54.7%±0.41%,which was significantly lower than that in the model group(70.92%±0.49%,P<0.05).Simultaneously,the expressions of gut tight junction proteins ZO-1 and Occludin showed an upward trend and validated transcription levels compared to the model group following rifaximin intervention(P<0.05).Conclusion Rifaximin can alleviate monocrotalineinduced hepatic sinusoidal obstruction syndrome in mice,and its mechanism may be via gut microbiota regulation,which in turn plays a role in improving intestinal barrier function.展开更多
Background:Pulmonary arterial hypertension(PH)is a progressive disease with limited therapeutic options,ultimately leading to right heart failure and death.Recent findings indicate the role of the Warburg effect(aerob...Background:Pulmonary arterial hypertension(PH)is a progressive disease with limited therapeutic options,ultimately leading to right heart failure and death.Recent findings indicate the role of the Warburg effect(aerobic glycolysis)in the development of PH.However,the effect of the glycolysis inhibitor 3-bromopyruvate(3-BrPA)on the pathogenesis of PH has not been well investigated.This study aimed to determine whether 3-BrPA inhibits PH and its possible mechanism.Methods:PH was induced in adult Sprague-Dawley rats by a single intraperitoneal injection of monocrotaline(MCT).3-BrPA,or phosphate-buffered saline(PBS)was administered via intraperitoneal injection every other day from the first day of MCT-injection to 4 weeks of follow-up,and indices such as right ventricular systolic pressure(RVSP),right ventricular hypertrophy index(RVHI),pulmonary arteriolar remodeling indicated by percent media thickness(%MT),lactate levels and glucose consumption,were evaluated.Pulmonary arteriolar remodeling and right ventricular hypertrophy were observed in hematoxylin-eosin-stained lung sections.Western blotting,immunohistochemistry,and/or immunofluorescence analyses were used to measure the expression of relevant proteins.A cytochrome C release apoptosis assay and terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end-labeling staining were used to measure cell apoptosis.Results:MCT-induced PH showed a significant increase in glucose consumption(0 vs.4 weeks:0.87±0.23 vs.2.94±0.47,P=0.0042)and lactate production(0 vs.4 weeks:4.19±0.34 vs.8.06±0.67,P=0.0004).Treatment with 3-BrPA resulted in a concomitant reduction in glucose consumption(1.10±0.35 vs.3.25±0.47,P=0.0063),lactate production(5.09±0.55 vs.8.06±0.67,P=0.0065),MCT-induced increase in RVSP(39.70±2.94 vs.58.85±2.32,P=0.0004),pulmonary vascular remodeling(%MT,43.45%±1.41%vs.63.66%±1.78%,P<0.0001),and right ventricular hypertrophy(RVHI,38.57%±2.69%vs.62.61%±1.57%,P<0.0001)when compared with those of the PBS-treated group.3-BrPA,a hexokinase 2 inhibitor,exerted its beneficial effect on PH by decreasing aerobic glycolysis and was also associated with inhibiting the expression of glucose transporter protein-1,inducing apoptosis,and suppressing inflammation.Conclusions:3-BrPA might have a potential beneficial effect on the PH treatment.展开更多
Pulmonary hypertension(PH) is clinically divided into 5 major types, characterized by elevation in pulmonary arterial pressure(PAP) and pulmonary vascular resistance(PVR), finally leading to right heart failure and de...Pulmonary hypertension(PH) is clinically divided into 5 major types, characterized by elevation in pulmonary arterial pressure(PAP) and pulmonary vascular resistance(PVR), finally leading to right heart failure and death. The pathogenesis of this arteriopathy remains unclear, leaving it impossible to target pulmonary vascular remodeling and reverse the deterioration of right ventricular(RV) function. Different animal models have been designed to reflect the complex mechanistic origins and pathology of PH, roughly divided into 4 categories according to the modeling methods: noninvasive models in vivo, invasive models in vivo, gene editing models, and multi-means joint modeling. Though each model shares some molecular and pathological changes with different classes of human PH, in most cases the molecular etiology of human PH is poorly known. The appropriate use of classic and novel PH animal models is essential for the hunt of molecular targets to reverse severe phenotypes.展开更多
Aim DL0805-2 is a novel Rho-kinases inhibitor which has been found to have potent cardiovascular effects. In the present research, we aimed to study the potential of DL0805-2 in the treatment of pulmonary arterial hyp...Aim DL0805-2 is a novel Rho-kinases inhibitor which has been found to have potent cardiovascular effects. In the present research, we aimed to study the potential of DL0805-2 in the treatment of pulmonary arterial hypertension （PAH） and discuss the underlying mechanisms preliminarily. Methods A classical PAH animal model was used, which was established by single injection of 50 mg · kg^-1 monocrotaline （MCT）. One week later, the rats were administrated with 1, 3, 10 mg · kg^-1 DL0805-2 via intraperitoneal injection for 18 days. At the end of the experiment, the body weight and survival rate were recorded. Meanwhile, the respiration function, heart function, blood pressure and pulmonary artery pressure were detected. Serum was collected for biochemical index analysis. The weight of vital organs was used to calculate the organ index. Histopathology examination was em-ployed to observe the subtle changes in hearts, vessels and lungs. Furthermore, the mechanisms were studied main- ly by the method of western blotting. Results DL0805-2 did not show significant influence on body weight of PAH rats. But the survival rate of PAH rats treated with 3 and 10 mg · kg^-1 DL0805-2 was increased up to 90. 9% com- pared with the model group （68.2%）. DL0805-2 improved the pulmonary artery blood flow especially the maximal -1 -1 velocity （PV max） from 397.2 cm · s^-1 to 506.5, 540. 1 and 574.0 cm · s^-1 respectively. The results of echocar- diography and electrocardiogram show that DL0805-2 had little effect on left ventricle and systemic circulation but attenuated right ventricle injury and decreased the right ventricle pressure from 73.73 mmHg to 47.80, 42.64 and 46.45 mmHg respectively after DL0805-2 intervention. Disease markers of PAH including NT-proBNP in serum and ET-1 in lung tissue homogenate and serum biochemical indicators, ALT, AST and LDH, were reduced by DL0805-2. DL0805-2 also relieved edema of lungs and decreased inflammatory cytokines production. Through the examination on histopathologic slide of pulmonary main artery, right ventricle and lung, DL0805 derivatives were found to have significant protection effect on structural changes of organs induced by pulmonary hypertension. Ac- cording to the preliminary study on the mechanisms of DL0805-2 in PAH, Rho/ROCK pathway was significantly in- hibited by DL0805 derivatives. In addition, DL0805 derivatives showed effect on BMPRII/p-Smad pathway and ap- optosis related pathway. Conclusion DL0805-2 has showed potent treatment effect on the PAH rats. And the un- derlying mechanisms studies also indicated that RhoA/ROCK and BMPRII pathways were involved. This work will provide basis experimental data for the further research and development of DL0805-2.展开更多
基金College of Medicine and Public Health,MD,Advanced Studies ProgramAustralian National Health and Medical Research Council(NHMRC),Grant/Award Number:GNT2003683。
文摘The COVID-19 pandemic posed a challenge for clinical management of a new lung disease that was characterized by inflammation,endothelial cell dysfunction,and thrombosis,which occur after the replication phase of infection of severe acute respiratory syndrome coronavirus 2(SARS-CoV-2).There are many laboratory models of active SARS-CoV-2 infection in mice,reflecting an acute lung injury in an otherwise healthy animal,but there is a lack of accurate animal models of the postviral inflammatory phase of the COVID-19 lung reflecting severe disease.The monocrotaline(MCT)-treated rat is a widely used laboratory model of pulmonary hypertension(PH).Not often discussed,however,are the observed changes in inflammation,edema,fibrosis,and microthrombosis in the lung prior to PH.At the cellular level,there is loss of pneumocytes and endotheliopathy,and at the molecular level the MCT rat lung is characterized by a proinflammatory cytokine profile,namely elevated interleukin 6,transforming growth factorβand tumor necrosis factor,M1 macrophage phenotype,and dysregulation of the angiotensin converting enzyme(ACE)/ACE2 balance.The systems-level pathophysiology of the MCT-treated rat includes progressive cardiopulmonary dysfunction.The MCT-treated rat clearly differs from the COVID-19 lung in terms of the triggers for pathology,but there are many parallels apparent in both the MCT-treated rat and the COVID-19 lung.The MCT-treated rat lung as a model of the COVID-19 lung may provide an in-depth understanding of the factors that drive the lung to more severe pathology,treatments that benefit lung recovery,or the factors that prove a useful research platform for future emerging respiratory threats of similar pathology.
文摘Pulmonary arterial hypertension （PAH） is a progressive disease associated with increased constriction and remodeling of the pulmonary vasculature. Quercetin is a natural fiavonoid and has a variety of pharmacological effects including improvement of endothelial cell function. However, its pharmacological effects on pulmonary hypertension have been rarely reported. We sought to observe the protective effect of quercetin in rats with monocrotaline induced PAH. We divided 30 male Sprague-Dawley rats randomly into three groups with ten rats in each group： the monocrotaline group, the quercetin group and the control group. We found that, compared with the controls, the mean pulmonary artery pressure （mPAP） and the right ventricular hypertrophy index in the monocrotaline group were significantly higher （P 〈 0.01）. Quercetin caused a significant reduction both in the mPAP and fight ventricular hypertrophy index compared with the monocrotaline group （P 〈 0.01） while no difference was found between the quercefin group and the control group （P 〉 0.05）. Monocrotaline induced a marked increase in the wall thickness （WT） in small and mid-sized pulmonary arteries compared with the controls （P 〈 0.01）. Monocrotaline also induced a marked increase in the wall area （WA） in small [（56.38 ±6.65）% in monocrotaline vs. （19.80±4.63）% in control] and mid-sized [（43.71± 5.38）% in monocrotaline vs. （14.24± 3.66）% in control] pulmonary arteries （P 〈 0.01）. Quercefin treatment markedly reduced monocrotaline induced increase in both WT and WA （P 〈 0.01）, which, however, still remained significantly elevated compared with those of the controls （P 〈 0.01）. Furthermore, compared with controls, proliferating cell nuclear antigen （PCNA） expression in the pulmonary artery tissues was markedly increased by monocrotaline [（45.59± 1.27） in monocrotaline vs. （9.64± 0.69） in controls], which was significantly attenuated by quercetin. Our animal experiment indicated that quercetin could have protective effects on monocrotaline-induced PAH.
文摘BACKGROUND:Hepatic veno-occlusive disease(HVOD)is a severe complication of chemotherapy before hematopoietic stem cell transplantation and dietary ingestion of pyrrolizidine alkaloids.Many experimental models were established to study its mechanisms or therapy,but few are ideal.This work aimed at evaluating a rat model of HVOD induced by monocrotaline to help advance research into this disease. METHODS:Thirty-two male rats were randomly classified into 5 groups,and PBS or monocrotaline was administered (100 mg/kg or 160 mg/kg).They were sacrificed on day 7(groups A,B and D)or day 10(groups C and E).Blood samples were collected to determine liver enzyme concentrations.The weight of the liver and body and the amount of ascites were measured.Histopathological changes of liver tissue on light microscopy were assessed by a modified Deleve scoring system.The positivity of proliferating cell nuclear antigen(PCNA)was estimated. RESULTS:The rats that were treated with 160 mg/kg monocrotaline presented with severe clinical symptoms (including two deaths)and the histopathological picture of HVOD.On the other hand,the rats that were fed with 100 mg/kg monocrotaline had milder and reversible manifestations.Comparison of the rats sacrificed on day 10 with those sacrificed on day 7 showed that the positivity of PCNA increased,especially that of hepatocytes.CONCLUSIONS:Monocrotaline induces acute,dose- dependent HVOD in rats.The model is potentially reversible with a low dose,but reliable and irreversible with a higher dose.The modified scoring system seems to be more accurate than the traditional one in reflecting the histopathology of HVOD.The enhancement of PCNA positivity may be associated with hepatic tissue undergoing recovery.
基金supported by the Natural Science Foundation of Guangdong Province(No.2018A0303100026)German Research Foundation(DFG) Grant Clinical Research Group “Genotype-phenotype relationships and neurobiology of the longitudinal course of psychosis” in work package 3(No. BR2471/1-1) and DFG Grant(No. TZ74/1-1)
文摘Current study systematically investigated the interaction of two alkaloids, anisodine and monocrotaline, with organic cation transporter OCT1, 2, 3, MATE1 and MATE2-K by using in vitro stably transfected HEK293 cells. Both anisodine and monocrotaline inhibited the OCTs and MATE transporters. The lowest IC50 was 12.9 μmol·L-1 of anisodine on OCT1 and the highest was 1.8 mmol·L-1 of monocrotaline on OCT2. Anisodine was a substrate of OCT2(Km = 13.3 ± 2.6 μmol·L-1 and Vmax = 286.8 ± 53.6 pmol/mg protein/min). Monocrotaline was determined to be a substrate of both OCT1(Km = 109.1 ± 17.8 μmol·L^-1, Vmax = 576.5 ± 87.5 pmol/mg protein/min) and OCT2(Km = 64.7 ± 14.8 μmol·L^-1, Vmax = 180.7 ± 22.0 pmol/mg protein/min), other than OCT3 and MATE transporters. The results indicated that OCT2 may be important for renal elimination of anisodine and OCT1 was responsible for monocrotaline uptake into liver. However neither MATE1 nor MATE2-K could facilitate transcellular transport of anisodine and monocrotaline. Accumulation of these drugs in the organs with high OCT1 expression(liver) and OCT2 expression(kidney) may be expected.
文摘To observe changes in activity of superoxide dismutase (SOD) and content of malondialdehyde (MDA) in rats with monocrotaline-induced pulmonary hypertension. Methods: Adult ma1e Sprague-Dawley rats were given a single subcutaneous injection of monocrotaline (MCT, 60 mg/kg) for modeling PH. Activities of SOD and contents of MDA in plasma and pulmonary homogenate were measured by colorimetric analysis. The thickness of the media of pulmonary arterioles (external diameter <100μm) was measured using colour image analysis system. Results: Four weeks after injection of MCT, activities of SOD in venous plasma and pulmonary homogenate for MCT group were 106±45 NU/ml (P<0.05) and 317±59 NU/ml (P<0.01) respectively, whileactivities of SOD for control group were 159±28 NU/ml (P<0.05) and 505±47 NU/ml (P<0.01) respectively.COntents of MDA in venous plasma and pulmonary homogenate for MCT group were 15±5 and 59±14 μmol/L,while contents of MDA for control group were 5. 3±2. 8 and 32±19 ±mol/L. The thickness of the media of pulmonary arterioles increased significantly. Conclusion: The primary cause of PH is the injury of pulmonary vascular endothelial cells by MCT, which decreases the O2 removing ability of the lungs but increases lipid peroxidation,thus inducing PH.
文摘Precision-cut liver slice has been successfully used to study the mechanism of drug-induced hepatotoxicity, the prediction of liver toxicity, the discovery of early hepatic toxicity biomarker and the metabolism of drug in liver. We detected the expression of CYP3A4, CYP2B1 + CYP2B2 and CYP2E1 in precision-cut liver slice after co-cultured with monocrotaline or Tussilago farfara alkaloids to investigate the hepatotoxicity mechanism of those drugs. After co-culturing with monocrotaline or Tussilago farfara alkaloids for 6 hours, the expression of CYP3A4 in the microsome of precision-cut liver slices was detected by Western blot, and the expressions of CYP2B1 + CYP2B2 and CYP2E1 were detected by immunofluorescence. The results showed that monocrotaline induced the expression of CYP3A4 and CYP2B1 + CYP2B2, and Tussilago farfara alkaloids obviously up-regulated the expression of CYP2E1 and CYP3A4. Thus, we conclude that the up-regulation of CYP3A4, CYP2B1 + CYP2B2 and CYP2E1 may be one of the toxic mechanisms of liver injury of those drugs.
基金supported by the Senior Research Fellowship from the Indian Council of Medical Research,Govt of India through the research grant to ASBsupported by an extramural research grant from the Indian Council of Medical Research to ASB(5/4/1-9/2019-NCD-Ⅱ)financially supported by Dr.TMA Pai Fellowship from Manipal Academy of Higher Education,Manipal.
文摘Exercise training in pulmonary arterial hypertension(PAH)has been gaining popularity with guidelines now recommending it as an important adjunct to medical therapy.Despite improvements in function and quality of life,an understanding of metabolic changes and their mechanisms remain unexplored.The objective of this study was therefore to understand the metabolic basis of exercise in a monocrotaline model of PAH.24 male Wistar rats(age:8–12 weeks and mean body weight:[262.16±24.49]gms)were assigned to one of the four groups(i.e.,Control,PAH,Exercise and PAH t Exercise).The exercise groups participated in treadmill running at 13.3 m/min,five days a week for five weeks.Demographic and clinical characteristics were monitored regularly.Following the intervention,LC-MS based metabolomics were performed on blood samples from all groups at the end of five weeks.Metabolite profiling,peak identification,alignment and isotope annotation were also performed.Statistical inference was carried out using dimensionality reducing techniques and analysis of variance.Partial-least-squares discrimination analysis and variable importance in the projection scores showed that the model was reliable,and not over lifting.The analysis demonstrated significant perturbations to lipid and amino acid metabolism,arginine and homocysteine pathways,sphingolipid(p<0.05),glycerophospholipid(p<0.05)and nucleotide metabolism in PAH.Exercise,however,was seen to restore arginine(p<0.05)and homocysteine(p<0.0001)levels which were independent effects,irrespective of PAH.Dysregulated arginine and homocysteine pathways are seen in PAH.Exercise restores these dysregulated pathways and could potentially impact severity and outcome in PAH.
文摘Objective To investigate the curative effect and possiblemechanism ofrifaximin treatment on monocrotaline-induced hepatic sinusoidal obstruction syndrome(HSOS)in mice.Methods Twenty-four male C57BL/6J mice were divided into three groups and treatedwith solvent tcontrol,monocrotaline,and rifaximin,respectively.The histopathological changes of the liver and intestine were observed by hematoxylineosin staining.The differences were compared in liver parameters,serum liver enzymes,inflammatory factors,apoptotic factors,gut microbiota,and gut tight junction proteins among three groups of mice.The inter-group comparison was conducted using a t-test and one-way analysis of variance.Results The rifaximin-treated group had significantly improved liver histopathology.The serological levels of alanine aminotransferase and aspartate aminotransferase were(559.04±89.42)U/L and(676.90±106.25)U/L,respectively,which were significantly lower than those in the PA-HSOS model group[(846.05±148.46)U/L and(953.87±58.10)U/L,P<0.05],and were accompanied by lower levels of apoptotic cells and inflammatory factors.Additionally,the rifaximintreated mice group gut microbiota had higher diversity compared with the PA-HSOS group(P<0.05),and the Shannon index was 7.77±0.10 and 7.16±0.07,respectively,indicating apparent differences in microbiota among different groups.The abundance of Firmicutes in the rifaximin group was 39.58%±0.56%,which was significantly higher than that in the model group(24.25%±0.64%,P<0.05),while the abundance of Bacteroidetes was 54.7%±0.41%,which was significantly lower than that in the model group(70.92%±0.49%,P<0.05).Simultaneously,the expressions of gut tight junction proteins ZO-1 and Occludin showed an upward trend and validated transcription levels compared to the model group following rifaximin intervention(P<0.05).Conclusion Rifaximin can alleviate monocrotalineinduced hepatic sinusoidal obstruction syndrome in mice,and its mechanism may be via gut microbiota regulation,which in turn plays a role in improving intestinal barrier function.
基金This work was supported by grants from the National Natural Science Foundation of China(No.31600939)the Beijing Natural Science Foundation(No.7174280)the Beijing Talents Training Project(No.2015000020124G111).
文摘Background:Pulmonary arterial hypertension(PH)is a progressive disease with limited therapeutic options,ultimately leading to right heart failure and death.Recent findings indicate the role of the Warburg effect(aerobic glycolysis)in the development of PH.However,the effect of the glycolysis inhibitor 3-bromopyruvate(3-BrPA)on the pathogenesis of PH has not been well investigated.This study aimed to determine whether 3-BrPA inhibits PH and its possible mechanism.Methods:PH was induced in adult Sprague-Dawley rats by a single intraperitoneal injection of monocrotaline(MCT).3-BrPA,or phosphate-buffered saline(PBS)was administered via intraperitoneal injection every other day from the first day of MCT-injection to 4 weeks of follow-up,and indices such as right ventricular systolic pressure(RVSP),right ventricular hypertrophy index(RVHI),pulmonary arteriolar remodeling indicated by percent media thickness(%MT),lactate levels and glucose consumption,were evaluated.Pulmonary arteriolar remodeling and right ventricular hypertrophy were observed in hematoxylin-eosin-stained lung sections.Western blotting,immunohistochemistry,and/or immunofluorescence analyses were used to measure the expression of relevant proteins.A cytochrome C release apoptosis assay and terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end-labeling staining were used to measure cell apoptosis.Results:MCT-induced PH showed a significant increase in glucose consumption(0 vs.4 weeks:0.87±0.23 vs.2.94±0.47,P=0.0042)and lactate production(0 vs.4 weeks:4.19±0.34 vs.8.06±0.67,P=0.0004).Treatment with 3-BrPA resulted in a concomitant reduction in glucose consumption(1.10±0.35 vs.3.25±0.47,P=0.0063),lactate production(5.09±0.55 vs.8.06±0.67,P=0.0065),MCT-induced increase in RVSP(39.70±2.94 vs.58.85±2.32,P=0.0004),pulmonary vascular remodeling(%MT,43.45%±1.41%vs.63.66%±1.78%,P<0.0001),and right ventricular hypertrophy(RVHI,38.57%±2.69%vs.62.61%±1.57%,P<0.0001)when compared with those of the PBS-treated group.3-BrPA,a hexokinase 2 inhibitor,exerted its beneficial effect on PH by decreasing aerobic glycolysis and was also associated with inhibiting the expression of glucose transporter protein-1,inducing apoptosis,and suppressing inflammation.Conclusions:3-BrPA might have a potential beneficial effect on the PH treatment.
基金CAMS Innovation Fund for Medical Sciences (CIFMS):2021-I2M-1-018。
文摘Pulmonary hypertension(PH) is clinically divided into 5 major types, characterized by elevation in pulmonary arterial pressure(PAP) and pulmonary vascular resistance(PVR), finally leading to right heart failure and death. The pathogenesis of this arteriopathy remains unclear, leaving it impossible to target pulmonary vascular remodeling and reverse the deterioration of right ventricular(RV) function. Different animal models have been designed to reflect the complex mechanistic origins and pathology of PH, roughly divided into 4 categories according to the modeling methods: noninvasive models in vivo, invasive models in vivo, gene editing models, and multi-means joint modeling. Though each model shares some molecular and pathological changes with different classes of human PH, in most cases the molecular etiology of human PH is poorly known. The appropriate use of classic and novel PH animal models is essential for the hunt of molecular targets to reverse severe phenotypes.
文摘Aim DL0805-2 is a novel Rho-kinases inhibitor which has been found to have potent cardiovascular effects. In the present research, we aimed to study the potential of DL0805-2 in the treatment of pulmonary arterial hypertension （PAH） and discuss the underlying mechanisms preliminarily. Methods A classical PAH animal model was used, which was established by single injection of 50 mg · kg^-1 monocrotaline （MCT）. One week later, the rats were administrated with 1, 3, 10 mg · kg^-1 DL0805-2 via intraperitoneal injection for 18 days. At the end of the experiment, the body weight and survival rate were recorded. Meanwhile, the respiration function, heart function, blood pressure and pulmonary artery pressure were detected. Serum was collected for biochemical index analysis. The weight of vital organs was used to calculate the organ index. Histopathology examination was em-ployed to observe the subtle changes in hearts, vessels and lungs. Furthermore, the mechanisms were studied main- ly by the method of western blotting. Results DL0805-2 did not show significant influence on body weight of PAH rats. But the survival rate of PAH rats treated with 3 and 10 mg · kg^-1 DL0805-2 was increased up to 90. 9% com- pared with the model group （68.2%）. DL0805-2 improved the pulmonary artery blood flow especially the maximal -1 -1 velocity （PV max） from 397.2 cm · s^-1 to 506.5, 540. 1 and 574.0 cm · s^-1 respectively. The results of echocar- diography and electrocardiogram show that DL0805-2 had little effect on left ventricle and systemic circulation but attenuated right ventricle injury and decreased the right ventricle pressure from 73.73 mmHg to 47.80, 42.64 and 46.45 mmHg respectively after DL0805-2 intervention. Disease markers of PAH including NT-proBNP in serum and ET-1 in lung tissue homogenate and serum biochemical indicators, ALT, AST and LDH, were reduced by DL0805-2. DL0805-2 also relieved edema of lungs and decreased inflammatory cytokines production. Through the examination on histopathologic slide of pulmonary main artery, right ventricle and lung, DL0805 derivatives were found to have significant protection effect on structural changes of organs induced by pulmonary hypertension. Ac- cording to the preliminary study on the mechanisms of DL0805-2 in PAH, Rho/ROCK pathway was significantly in- hibited by DL0805 derivatives. In addition, DL0805 derivatives showed effect on BMPRII/p-Smad pathway and ap- optosis related pathway. Conclusion DL0805-2 has showed potent treatment effect on the PAH rats. And the un- derlying mechanisms studies also indicated that RhoA/ROCK and BMPRII pathways were involved. This work will provide basis experimental data for the further research and development of DL0805-2.
